All In Biotech

Drug Trial Radar · NCT03158311

Study to Compare QVM149 and Free Triple Combination of Salmeterol/Fluticasone + Tiotropium

A Multicenter, Partially-Blinded, Randomized, 24-Week, Parallel-Group, Non-Inferiority, Open-Label Active Controlled Study to Compare the Efficacy and Safety of QVM149 With a Free Triple Combination of Salmeterol/Fluticasone + Tiotropium in Patients With Uncontrolled Asthma

Last checked: Nov 19, 2026Latest source record: Oct 8, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,426 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,426

Actual

Start

Feb 5, 2018

Primary completion

Jul 12, 2019

Study completion Jul 19, 2019

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
May 18, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Single (outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this trial was to demonstrate that the efficacy of two treatment arms of the fixed-dose combination product QVM149 was non-inferior to the efficacy of the free combination arm of salmeterol/ fluticasone+ tiotropium in uncontrolled moderate to severe asthmatic patients. The planned duration of treatment in this study was 24 weeks, followed up by a 7-day follow-up period.

Conditions

  • Asthma

Interventions

  • QVM149Drug

    Indacaterol acetate / glycopyrronium bromide / mometasone furoate

  • Salmeterol/fluticasone plus tiotropiumDrug

    Free triple arm of salmeterol / fluticasone plus tiotropium

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline in Asthma Quality of Life Questionnaire (AQLQ) Total ScoreTime frame: Baseline and Week 24

Locations

163 sites in 20 countries. Site status is shown where the registry gives one.

  • Novartis Investigative Site

    Bahía Blanca, Argentina

  • Novartis Investigative Site

    Buenos Aires, Argentina

  • Novartis Investigative Site

    Buenos Aires, Argentina

  • Novartis Investigative Site

    Buenos Aires, Argentina

  • Novartis Investigative Site

    Buenos Aires, Argentina

  • Novartis Investigative Site

    Ciudad Autonoma de Bs As, Argentina

  • Novartis Investigative Site

    Mendoza, Argentina

  • Novartis Investigative Site

    Mendoza, Argentina

  • Novartis Investigative Site

    Mendoza, Argentina

  • Novartis Investigative Site

    Salta, Argentina

  • Novartis Investigative Site

    Santa Fe, Argentina

  • Novartis Investigative Site

    Berazategui, Buenos Aires, Argentina

  • Novartis Investigative Site

    Caba, Buenos Aires, Argentina

  • Novartis Investigative Site

    CABA, Buenos Aires, Argentina

  • Novartis Investigative Site

    CABA, Buenos Aires, Argentina

  • Novartis Investigative Site

    CABA, Buenos Aires, Argentina

  • Novartis Investigative Site

    CABA, Buenos Aires, Argentina

  • Novartis Investigative Site

    Florida, Buenos Aires, Argentina

  • Novartis Investigative Site

    Lanus, Buenos Aires, Argentina

  • Novartis Investigative Site

    Mar del Plata, Buenos Aires, Argentina

  • Novartis Investigative Site

    Nueve de Julio, Buenos Aires, Argentina

  • Novartis Investigative Site

    Ranelagh, Partido de Berazate, Buenos Aires, Argentina

  • Novartis Investigative Site

    Concepción del Uruguay, Entre Ríos Province, Argentina

  • Novartis Investigative Site

    Santa Rosa, La Pampa Province, Argentina

  • Novartis Investigative Site

    Buenos Aires, Nueve De Julio, Argentina

  • Novartis Investigative Site

    Rosario, Santa Fe Province, Argentina

  • Novartis Investigative Site

    Rosario, Santa Fe Province, Argentina

  • Novartis Investigative Site

    San Miguel de Tucumán, Tucumán Province, Argentina

  • Novartis Investigative Site

    Curicó, Maule Region, Chile

  • Novartis Investigative Site

    Santiago, Santiago Metropolitan, Chile

  • Novartis Investigative Site

    Bogotá, Colombia

  • Novartis Investigative Site

    Bogota, Cundinamarca, Colombia

  • Novartis Investigative Site

    Lovosice, Czechia

  • Novartis Investigative Site

    Miroslav, Czechia

  • Novartis Investigative Site

    Teplice, CZE, Czechia

  • Novartis Investigative Site

    Ostrava Poruba, Czech Republic, Czechia

  • Novartis Investigative Site

    Prague, Czech Republic, Czechia

  • Novartis Investigative Site

    Berlin, Germany

  • Novartis Investigative Site

    Berlin, Germany

  • Novartis Investigative Site

    Berlin, Germany

Showing 40 of 163 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.